Long-term clinical outcomes of Zikaassociated Guillain-Barré syndrome

Ver/
Fecha
2018-08
2018-08
Autor
Chang, Aileen Y.
Lynch, Rebecca
Martins, Karen
Encinales, Liliana
Cadena Bonfanti, Andrés Á.
Pacheco, Nelly
Reid, St. Patrick
Lara Sarabia, Osvaldo E.
González Torres, Henry J.
Mejia Castillo, Stella
Barrios Taborda, Onaldo
Alarcon Gomez, Magda
Guerra Duran, Brenda
Martinez Giraldo, Victor
Benitez Ospino, Angélica
Porras, Alexandra
Mendoza, Alejandro R.
Mantus, Grace
Li, Guangzhao
Peng, Jin
Kamalapathy, Priyanka
Avendaño Echavez, Lil G.
Dowd, Kimberly A.
Rengifo-Pardo, Monica
Barraza, Pedro Pablo
Jiménez Hernàndez, Dennys
González Coba, Andrés
De La Hoz Mendoza, Katya
Bethony, Jeffrey M.
Simon, Gary L.
Metadatos
Mostrar el registro completo del ítem
Mostrar el registro completo del ítem
Resumen
Zika virus infection has been associated with the development of a spectrum of neurologic disease including Guillain–Barré syndrome (GBS)1. GBS is an autoimmune disorder of the peripheral nervous system often triggered by a preceding infection. The mechanism of Zika-associated GBS (Z-GBS) and the long-term clinical course is unknown. The purpose of this study was to describe the 2-year clinical course of Z-GBS in order to provide further insights into disease pathogenesis and prognosis.
Enlace para referencia:
http://hdl.handle.net/20.500.12442/2237
http://hdl.handle.net/20.500.12442/2237
Enlace al recurso externo:
https://www.nature.com/articles/s41426-018-0151-9
https://www.nature.com/articles/s41426-018-0151-9